miRagen Clinical Trials

miRagen has three product candidates in clinical development:

  • Cobomarsen (MRG-106), an inhibitor of microRNA-155, is being developed for the treatment of blood cancers
  • Remlarsen (MRG-201), a synthetic replacement of microRNA-29 is being developed for the treatment or prevention of pathologic fibrosis
  • MRG-110 (S95010), an inhibitor of microRNA-92, is being developed in collaboration with Servier for the treatment of heart failure or other ischemic conditions where blood flow into tissues is compromised

If you are a patient, please click here.